Clinical Trials Logo

Filter by:
NCT ID: NCT00195715 Completed - Crohn's Disease Clinical Trials

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Start date: September 2004
Phase: Phase 3
Study type: Interventional

To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.

NCT ID: NCT00195663 Completed - Clinical trials for Early Rheumatoid Arthritis

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

PREMIER
Start date: December 2000
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10 years.

NCT ID: NCT00195559 Completed - Clinical trials for Premenstrual Syndrome

Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.

NCT ID: NCT00195546 Completed - Menopause Clinical Trials

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Start date: April 2005
Phase: Phase 3
Study type: Interventional

Primary: To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone. Secondary: To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight, breast pain, and health outcomes indicators.

NCT ID: NCT00195507 Completed - Psoriasis Clinical Trials

Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis

Start date: December 2004
Phase: Phase 4
Study type: Interventional

This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.

NCT ID: NCT00191906 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)

Start date: April 2005
Phase: Phase 4
Study type: Interventional

To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.

NCT ID: NCT00191698 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD

Start date: December 2003
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of ODD in children with ADHD and ODD.

NCT ID: NCT00191464 Completed - Clinical trials for Diabetes Mellitus, Type 2

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Start date: December 2003
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to show that a prandial insulin regimen, consisting of premeal insulin lispro "mid mixture" (or a combined regimen of insulin lispro "mid mixture" and insulin lispro "low mixture") plus metformin will result in significantly better overall glycemic control (lower HbA1c) at endpoint than once-daily insulin glargine plus metformin. Insulin lispro "mid mixture" consists of 50% insulin lispro and 50% NPL. Insulin lispro "low mixture" consists of 25% insulin lispro and 75% NPL. In a substudy of approximately 60 patients, additional data will be collected on markers associated with risk of atherosclerosis or cardiovascular disease in the context of a controlled, outpatient, high-fat test meal.

NCT ID: NCT00191438 Completed - Breast Neoplasms Clinical Trials

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Start date: October 2002
Phase: Phase 3
Study type: Interventional

This is a phase III randomized study which compares two different regimens of chemotherapy. The purpose of the study is to determine which of the two regimens will make the tumor smaller or disappear, and for how long. In addition the disease-related symptoms will be evaluated. The safety of the drugs will be determined based upon evaluation of the side effects

NCT ID: NCT00190684 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Long-Term, Open Label Atomoxetine Study

Start date: August 2000
Phase: Phase 3
Study type: Interventional

To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term). Study participants can be atomoxetine naive, atomoxetine experienced whose therapy has been interrupted or, atomoxetine experienced on a known stable dose.